LeonaBio, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
LeonaBio reported Q2 2026 results with 495 of ~600 patients enrolled in Phase 3 ELAINE-3 trial for lasofoxifene (licensed from Sermonix in December 2025 for $90M financing). Cash declined 42% from $88.3M (Dec 2025) to $51.1M (June 2026); Q2 net operating cash burn was $37.9M vs. $21.7M YoY; R&D expenses tripled to $12.9M driven by ELAINE-3 clinical costs. Company expects enrollment completion Q4 2026 and topline data H2 2027. Up to $146M additional capital available from warrant exercises.
Why this rating
Major cash burn relative to $9.9M market cap (51% of current cash in one quarter) is concerning, but offset by on-track Phase 3 milestone and $146M warrant upside. Significant for trajectory but not imminent existential risk given capital availability.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.